Dr Gordon Hamilton, President & CEO of Depixus SAS, will be showcasing the company’s pioneering approach to transform RNA-targeted drug discovery at the upcoming Cambridge Healthtech Institute Discovery on Target Conference in Boston, USA, between 25 and 28 September 2023.
Progress in this space is hampered by a lack of effective methods to visualize and understand how RNA structures interact with their native ligands and candidate drugs. This major limitation can result in ineffective molecules being advanced through the drug development pipeline with consequent costly failure during late preclinical or early clinical stages.
Based on magnetic force spectroscopy, Depixus’ MAGNA™ technology enables high-throughput single molecule analysis of molecular interactions between small molecules and target RNAs in near-real time.
Hamilton’s presentation at 9.30am EST on Wednesday 27th September - entitled ‘Magnetic Force Spectroscopy: Improving Hit-to-Lead and Lead Optimization in RNA-targeted Small-Molecule Drug Discovery’ - will show how MAGNA™ provides powerful new insights into how drugs modulate RNA structures for therapeutic benefit, accelerating and de-risking drug discovery in this exciting, fast-emerging field.
CHI Discovery on Target is a leading global forum for sharing the latest breakthroughs in novel targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules, including the targeting of RNA by small molecule lead compounds.
About Depixus
Depixus SAS, Paris, is a venture funded life science technology company that is pioneering a ground-breaking technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. MAGNA™ enables researchers to decode disease mechanisms and unlock a faster route to more effective therapies.
Depixus is continuing to expand its partnerships with leaders in the development of novel RNA-targeted small molecule therapeutics. For more information, please visit www.depixus.com or email info@depixus.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20230920564429/en/
